Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLN-049 + azacitidine + venetoclax
- Development stage
- Phase 1
- Lead developer
- Cullinan Therapeutics
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
CLN-049 + azacitidine + venetoclax is an investigational combination regimen being evaluated for the treatment of newly diagnosed acute myeloid leukemia (AML). The regimen combines CLN-049, a novel bispecific T-cell engager targeting both mutated and non-mutated FLT3 and CD3, with the standard-of-care backbone of azacitidine (a hypomethylating agent) and venetoclax (a BCL-2 inhibitor). Developed by Cullinan Therapeutics, this combination is designed to enhance anti-leukemic activity by recruiting T cells to FLT3-expressing leukemia cells while simultaneously inducing apoptosis and epigenetic modifications. It is currently being evaluated in a Phase 1/2 clinical trial (NCT07722767) in patients with previously untreated AML who are unfit for intensive chemotherapy.
- Other names
- CLN-049 + venetoclax + azacitidineCLN-049, azacitidine, and venetoclaxCLN-049, venetoclax, and azacitidine
02
Targets
BCL-2 (BCL-2 family)DNMT1 (DNA (cytosine-5)-methyltransferase 1)DNMT3A (DNA methyltransferase 3 alpha)DNMT3B (DNA (cytosine-5)-methyltransferase 3B)FLT3 (Fms related receptor tyrosine kinase 3)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on CLN-049 + azacitidine + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLN-049 + azacitidine + venetoclax.